Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Mar 3;222(3):e20241424.
doi: 10.1084/jem.20241424. Epub 2025 Jan 24.

RNase T2 restricts TLR13-mediated autoinflammation in vivo

Affiliations

RNase T2 restricts TLR13-mediated autoinflammation in vivo

Carlos Gomez-Diaz et al. J Exp Med. .

Abstract

RNA-sensing TLRs are strategically positioned in the endolysosome to detect incoming nonself RNA. RNase T2 plays a critical role in processing long, structured RNA into short oligoribonucleotides that engage TLR7 or TLR8. In addition to its positive regulatory role, RNase T2 also restricts RNA recognition through unknown mechanisms, as patients deficient in RNase T2 suffer from neuroinflammation. Consistent with this, mice lacking RNase T2 exhibit interferon-dependent neuroinflammation, impaired hematopoiesis, and splenomegaly. However, the mechanism by which RNase T2 deficiency unleashes inflammation in vivo remains unknown. Here, we report that the inflammatory phenotype found in Rnaset2-/- mice is completely reversed in the absence of TLR13, suggesting aberrant accumulation of an RNA ligand for this receptor. Interestingly, this TLR13-driven inflammatory phenotype is also fully present in germ-free mice, suggesting a role for RNase T2 in limiting erroneous TLR13 activation by an as yet unidentified endogenous ligand. These results establish TLR13 as a potential self-sensor that is kept in check by RNase T2.

PubMed Disclaimer

Conflict of interest statement

Disclosures: W. Wurst reported a patent (W02014/131833) issued: “Generation of mouse models using CRISPR/Cas9 in zygotes is patented (WO2014/131833).” No other disclosures were reported.

References

    1. Akilesh, H.M., Buechler M.B., Duggan J.M., Hahn W.O., Matta B., Sun X., Gessay G., Whalen E., Mason M., Presnell S.R., et al. . 2019. Chronic TLR7 and TLR9 signaling drives anemia via differentiation of specialized hemophagocytes. Science. 363:eaao5213. 10.1126/science.aao5213 - DOI - PMC - PubMed
    1. Berouti, M., Lammens K., Heiss M., Hansbauer L., Bauernfried S., Stockl J., Pinci F., Piseddu I., Greulich W., Wang M., et al. . 2024. Lysosomal endonuclease RNase T2 and PLD exonucleases cooperatively generate RNA ligands for TLR7 activation. Immunity. 57:1482–1496.e8. 10.1016/j.immuni.2024.04.010 - DOI - PMC - PubMed
    1. Black, S., Phillips D., Hickey J.W., Kennedy-Darling J., Venkataraaman V.G., Samusik N., Goltsev Y., Schürch C.M., and Nolan G.P.. 2021. CODEX multiplexed tissue imaging with DNA-conjugated antibodies. Nat. Protoc. 16:3802–3835. 10.1038/s41596-021-00556-8 - DOI - PMC - PubMed
    1. Concordet, J.P., and Haeussler M.. 2018. CRISPOR: Intuitive guide selection for CRISPR/Cas9 genome editing experiments and screens. Nucleic Acids Res. 46:W242–W245. 10.1093/nar/gky354 - DOI - PMC - PubMed
    1. Crow, Y.J., and Stetson D.B.. 2022. The type I interferonopathies: 10 years on. Nat. Rev. Immunol. 22:471–483. 10.1038/s41577-021-00633-9 - DOI - PMC - PubMed

LinkOut - more resources